摘要
目的观察急性期多发性硬化(MS)患者血浆和脑脊液基质金属蛋白酶-9(MMP-9)水平的动态变化规律及其与临床神经功能障碍的相关性,探讨其对疾病活动性的判定价值。方法收集急性期MS患者、缓解期MS患者、健康对照各30例,神经系统非炎性疾病(NIND)17例,采用酶联免疫吸附试验法(ELISA)检测血浆和脑脊液MMP-9水平,并进行EDSS评分。结果 (1)与急性发作期初期相比,急性期MS患者第1、2周血浆MMP-9水平明显升高(P=0.019;P=0.014),第4周其脑脊液水平明显降低(P=0.014)。(2)急性期MS组血浆MMP-9水平明显高于缓解期组和健康对照组(P<0.01)。(3)与NIND组比较,急性期MS组脑脊液MMP-9水平明显升高(P<0.01)。(4)在MS急性期血浆与脑脊液MMP-9水平呈正相关(r=0.571,P=0.016),两者与患者同期EDSS评分之间无相关性(P>0.05)。结论 (1)MS患者血浆MMP-9水平可成为监测疾病活动的指标。(2)脑脊液MMP-9水平对鉴别MS患者与NIND有一定帮助。(3)在一定程度上急性期MS组血浆MMP-9水平可以代表脑脊液中的水平。
Objective To observe the dynamic changes of matrix metalloproteinase-9 （MMP-9） levels in plasma and cerebrospinal fluid （CSF）, and further to evaluate its relation with neurological disability in multiple sclerosis （MS）. To explore its values in the evaluation of MS activity. Methods Thirty patients with definite MS in relapsing state （relapsing MS group） according to the McDonald criteria, thirty patients with definite MS in remitting state （remitting MS group）, seventeen patients with noninflammatory neurologic disease （NIND, NIND group） and thirty healthy controls were enrolled in the study. Their clinical status were evaluated with the Expanded Disability Status Scale （EDSS）. Plasma and CSF levels of MMP-9 were analyzed by enzyme-linked immunoassay （ELISA）. Results （1） The MMP-9 level of the relapsing MS group in plasma elevated significantly in the 1st and 2nd weeks after relapsing （P=0. 019; P=0. 014）, that in CSF （n=17） decreased significantly in the 4th week after relapsing （P = 0. 014）. （2） The MMP-9 plasma level of the relapsing MS group （n=30） was significantly higher than that of the health control group and remitting MS group （P〈0.01）. （3） The MMP-9 level of the relapsing MS group in CSF was significantly higher than that of the NIND group （P〈0.01）. （4） The MMP9 level in plasma had positive correlation with that in CSF during the acute phase of MS （r=0. 571, P=0. 016）, both of them had no correlation with EDSS scores （P〉0.05）. Conclusions The MMP-9 level in plasma of MS may be a biomarker reflecting the activity of disease. MMP-9 level in plasma and CSF of patients may be used to differentiate MS from NIND. MMP-9 level in plasma of MS patients may reflect that in CSF.
出处
《中国神经免疫学和神经病学杂志》
CAS
2010年第5期327-330,共4页
Chinese Journal of Neuroimmunology and Neurology
关键词
多发性硬化
基质金属蛋白酶-9
血浆
脑脊液
multiple sclerosis
matrix metalloproteinases-9
plasma
cerebrospinal fluid
作者简介
刘喷飓（现工作于首都医科大学附属北京安贞医院神经内科）
通讯作者：张星虎，Email：xhzhtiantan@hotmail．com.
